This randomized controlled study aims to investigate the effects of using a mobile app that integrates with wearable devices to monitor heart rate, check self-reported symptoms, provide disease-related information, and set medication reminders for patients with thyrotoxicosis. The study intends to evaluate how the use of the app affects disease progression, quality of life, and health-related behaviors associated with the disease.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Enrollment
100
Using a mobile app that integrates with wearable devices to monitor heart rate, check self-reported symptoms, provide disease-related information, and set medication reminders for patients with thyrotoxicosis.
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
RECRUITINGScores of quality of life assessed by SF-36 survey
Scores of quality of life assessed by SF-36 survey
Time frame: baseline (at enrollment)
Scores of quality of life assessed by SF-36 survey
Scores of quality of life assessed by SF-36 survey
Time frame: 6 weeks after baseline
Scores of quality of life assessed by SF-36 survey
Scores of quality of life assessed by SF-36 survey
Time frame: 10 weeks after baseline
Scores of quality of life assessed by SF-36 survey
Scores of quality of life assessed by SF-36 survey
Time frame: 14 weeks after baseline
antithyroidal drug compliance
Medication adherence assessed by directly counting the remaining pills after taking the prescribed medication.
Time frame: 6 weeks after baseline
antithyroidal drug compliance
Medication adherence assessed by directly counting the remaining pills after taking the prescribed medication.
Time frame: 10 weeks after baseline
antithyroidal drug compliance
Medication adherence assessed by directly counting the remaining pills after taking the prescribed medication.
Time frame: 14 weeks after baseline
Knowledge about hyperthyroidism
A score measured through a test designed to assess the knowledge level about Graves' disease
Time frame: 14 weeks after baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
free T4
serum free T4 concentration
Time frame: baseline
free T4
serum free T4 concentration
Time frame: 6 weeks after baseline
free T4
serum free T4 concentration
Time frame: 10 weeks after baseline
free T4
serum free T4 concentration
Time frame: 14 weeks after baseline
free T3
serum free T3 concentration
Time frame: baseline
free T3
serum free T3 concentration
Time frame: 6 weeks after baseline
free T3
serum free T3 concentration
Time frame: 10 weeks after baseline
free T3
serum free T3 concentration
Time frame: 14 weeks after baseline
TSH
serum free TSH concentration
Time frame: baseline
TSH
serum free TSH concentration
Time frame: 6 weeks after baseline
TSH
serum free TSH concentration
Time frame: 10 weeks after baseline
TSH
serum free TSH concentration
Time frame: 14 weeks after baseline